Natsimbio to be transferred to the management of Viktor Kharitonin’s structure

As CEO, Nizovtsev will solve strategic tasks for the further development of full-cycle pharmaceutical production of new drugs to strengthen the epidemiological security of the Russian Federation and ensure technological sovereignty in the field of immunobiology.

For 20 years, Aleksandr Nizovtsev held various management positions at enterprises producing medicines and medical devices. For example, he headed the Tyumen Plant of Medical Equipment and Instruments (TZMOI, part of the Pharmstandard-Medtekhnika group), held management positions at Pharmstandard, and headed the I.I. Mechnikov Biomed vaccine and allergen manufacturing enterprise, where vaccines for the National Immunization Calendar are produced.

Andrey Zagorskiy headed Natsimbio in 2017. In 2001, he graduated from the Law Faculty of the Far Eastern State University. At various times, he headed production facilities in the oil and gas sector, such as NK YUKOS, Inter RAO UES, Yakutgazprom and others, worked in senior positions in the forestry and transport industries. In 2016, he headed Pharm-Center CJSC. In January 2017, he headed Sintez OJSC (now Sintez PJSC), whose shareholders at that time were SIA International and Rostec. From there, the manager was invited to the position of Acting General Director of Natsimbio in August 2017, after Maryam Khubieva left the post. In November 2023, the pharmaceutical holding announced the extension of the contract with Zagorskiy for another 5 years.

JSC National Immunobiological Company (Natsimbio), according to information from open sources, is a 100% subsidiary of Rostec State Corporation. According to SPARK-Interfax, the legal entity was registered in 2013 in Moscow. The company's website states that the company's entry into the then-forming holding of the Rostec state corporation was planned from the very beginning. Natsimbio's revenue for 2024 is estimated at 15.5 billion rubles, net profit at 4.5 billion rubles.

The list of assets of Natsimbio includes the biopharmaceutical company Fort, which specializes in the production of vaccines for the prevention of socially significant infectious diseases, and the scientific and production association for medical immunobiological drugs Mikrogen.

The cooperation between Natsimbio and Pharmstandard was first announced in April 2015: the companies signed a memorandum on the joint development of drugs, including immunobiological and blood products, organizing a full cycle of their production. At the end of 2016, the companies entered into an agreement with the Italian Kedrion Biopharma on cooperation in order to implement a joint program for the production of drugs obtained from human blood plasma. During the partnership, Kirov Plasma JSC was established in 2017. In the context of this project, Natsimbio was assigned the status of the sole supplier of blood plasma products for the needs of the Ministry of Health, the Ministry of Defense, the Ministry of Emergency Situations, the Ministry of Internal Affairs, the Federal Medical and Biological Agency and other structures for 2016 and 2017. In exchange, the company was supposed to complete the construction of a plasma production plant in Kirov. The project was never implemented . In 2019, Kedrion withdrew from it, and Kirov Plasma JSC was liquidated. However, the sole supplier status was extended for 2018 and 2019.

In 2022-2023, Natsimbio acted as the sole contractor for processing blood plasma for the needs of the Federal Medical and Biological Agency of Russia and the production of immunoglobulins.

In the summer of 2015, Natsimbio became the sole supplier of vaccines for the period 2015–2017 according to the National Immunization Schedule for the first time. The Russian Government extends this status every two years: for 2018–2019 , 2020–2021 , 2022–2023 . The last time a thematic order was published was at the end of February 2024 – contracts with a deadline of no later than December 31, 2025 may be concluded with the company.

Natsimbio's asset, Mikrogen, is the largest manufacturer of vaccines purchased in Russia using state budget funds, according to Headway, a company that monitors tender purchases in the pharmaceutical industry. In 2024, its drugs were purchased through state purchases for a total of 14.3 billion rubles - the manufacturer occupies more than 21% of the domestic vaccine market. Another asset of the pharmaceutical holding, Fort, took a share of 19.1% last year and supplied medical institutions with drugs for a total of 12.9 billion rubles. Thus, Natsimbio now occupies 30% of the national vaccine market.

Nanolek, another major domestic vaccine manufacturer (2% of the market, sold vaccines worth 1.4 billion rubles through government procurement in 2024), is also 75% owned by Viktor Kharitonin's partners. In April 2024, 25% of the pharmaceutical company was transferred to DD Kalita of Vasily Kulkov, the son of one of the founders of Pharmstandard, Yegor Kulkov. In January 2025, it became known that K2 Group, also affiliated with Pharmstandard, had withdrawn from the authorized capital of Nanolek. Gennady Shveigert and Pavel Mileiko, Kharitonin's partners, then each transferred 25% of the company.

Another Russian commercial structure, Petrovax, is among the top ten largest vaccine producers for Russian institutions. In 2024, it sold vaccines worth 9.5 billion rubles through government procurement, thus taking a share of 14%.